NIH Schedules Closed Grant Review Meetings
Published Date: 6/8/2026
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Closed virtual grant-review meetings
The NIH Center for Scientific Review will hold several closed virtual meetings on July 7–9, 2026 (with one panel meeting July 7–8) to review and decide on research grant applications. These meetings determine who gets funding for career development, fellowships, and research projects, and they are not open for public attendance.
Applicant privacy and trade-secret protection
The meetings will be closed under statutory exemptions to protect confidential trade secrets, commercial property (including patentable material), and personal information about people associated with the grant applications. That protection means applicants' sensitive research details and personal data will not be disclosed at these July 2026 review sessions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
Previous / Next Documents
Previous: 2026-11389, Pear Tree Funds and Pear Tree Advisors, Inc.
Pear Tree Funds and Pear Tree Advisors want to offer a new kind of investment fund that mixes regular mutual fund shares with exchange-traded fund (ETF) shares all in one. This change lets investors enjoy the best of both worlds—easy trading like ETFs and the flexibility of mutual funds. If approved, this could start soon, and folks interested have until June 29, 2026, to ask for a hearing.
Next: 2026-11391, Agency Information Collection Activities; Proposed Collection; Comment Request; Extension: Form 6-K-Exchange Act Rules 13a-16 and 15d-16
The SEC wants to keep using Form 6-K, which foreign companies file to share important news with U.S. investors quickly. About 1,261 companies file this form around 21 times a year, spending lots of time and money—over $35 million yearly on outside help! The SEC is asking for public feedback before extending this paperwork requirement to make sure it’s still useful and not too burdensome.